Nature Biotechnology
23, 1073 - 1078 (2005)
doi:10.1038/nbt0905-1073
Monoclonal antibody successes in the clinicJanice M Reichert, Clark J Rosensweig, Laura B Faden
& Matthew C Dewitz
Janice M. Reichert and Laura B. Faden are at Tufts University Center for the Study of Drug Development (CSDD), 192 South Street, Suite 550, Boston, Massachusetts 02111, USA. Clark J. Rosensweig and Matthew C. Dewitz were summer interns at CSDD. janice.reichert@tufts.edu
Most monoclonal antibodies in clinical trials are owned by small biotech companies. But with blockbuster-sized revenues and approval rates higher than those for small-molecule drugs, that all may be set to change.
MORE ARTICLES LIKE THIS These links to content published by NPG are automatically generated.
|
